OSBPL8

Across TCGA pan-cancer cohorts, OSBPL8 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated OSBPL8 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher OSBPL8 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OSBPL8 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC, KICH, and BLCA are the cancer types where OSBPL8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.040	0.553	<.001	18	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
BLCA	OS	Median	IV	0.085	0.605	<.001	12	view →
UCEC	DFS	Median	All	0.909	0.617	.020	10	view →
PAAD	DFS	Median	All	0.112	0.504	.025	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

OSBPL8–LIHC (DFS)

Open the LIHC breakdown →